← Leaderboards
Katherine Kurshan Matthay
University Of California San Francisco
$7,757,759
Attributed
$7,757,759
Total exposure
36
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $824.1K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,757,759 · 36
By mechanism
P01$5,689,797 · 4
M01$698,391 · 28
R21$522,012 · 1
P30$446,352 · 2
U10$401,207 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Stanley B Prusiner$54,781,835
- Thomas L James$6,218,651
- Fred E Cohen$5,735,573
- R Kiplin Guy$13,409,185
- Francis C Szoka$17,593,815
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationClinical Trial Phase IPediatric Neoplasm /CancerNeoplasm /Cancer ChemotherapyNeuroblastomaDrug Screening /EvaluationChild (0-11)Pediatric PharmacologyPharmacokineticsAntineoplasticsNeoplasm /Cancer ImmunotherapyCombination ChemotherapyTumorChildNeoplasm /Cancer PharmacologyNeoplasm /Cancer Relapse /RecurrenceAdolescence (12-20)FenretinideInjection /InfusionIntravenous AdministrationClinical TrialsLeukemia
Grant awards (121)
Clinical Trials and Translation$561,437
P01 · FY2018 · CA · contact PI
Pediatric Malignancies Program$86,469
P30 · FY2018 · CA · contact PI
Pediatric Malignancies Program$10,743
P30 · FY2018 · CA · contact PI
Pediatric Malignancies Program$8,603
P30 · FY2018 · CA · contact PI
Pediatric Malignancies Program$3,500
P30 · FY2018 · CA · contact PI
Clinical Trials and Translation$328,134
P01 · FY2017 · CA · contact PI
CLINICAL THERAPY TRIALS$405,218
P01 · FY2014 · CA · contact PI
CLINICAL THERAPY TRIALS$213,697
P01 · FY2013 · CA · contact PI
CLINICAL THERAPY TRIALS$417,566
P01 · FY2012 · CA · contact PI
CLINICAL THERAPY TRIALS$420,296
P01 · FY2011 · CA · contact PI
PEDIATRIC MALIGNANCIES PROGRAM$68,776
P30 · FY2011 · CA · contact PI
CLINICAL THERAPY TRIALS$439,902
P01 · FY2010 · CA · contact PI
PEDIATRIC MALIGNANCIES PROGRAM$68,638
P30 · FY2010 · CA · contact PI
CLINICAL THERAPY TRIALS$755,312
P01 · FY2009 · CA · contact PI
PEDIATRIC MALIGNANCIES PROGRAM$68,783
P30 · FY2009 · CA · contact PI
CLINICAL THERAPY TRIALS$557,066
P01 · FY2008 · CA · contact PI
PEDIATRIC MALIGNANCIES PROGRAM$70,316
P30 · FY2008 · CA · contact PI
CLINICAL THERAPY TRIALS$544,224
P01 · FY2007 · CA · contact PI
PEDIATRIC MALIGNANCIES PROGRAM$60,524
P30 · FY2007 · CA · contact PI
CLINICAL THERAPY TRIALS$530,997
P01 · FY2006 · CA · contact PI
CLINICAL THERAPY TRIALS$515,948
P01 · FY2005 · CA
131 I-MIBG DOUBLE INFUSION FOLLOWED BY STEM CELLS FOR REFRACTORY NEUROBLASTOMA$51,741
M01 · FY2005 · RR
131 I-LABELED MIBG FOR TREATMENT OF ADVANCED NEUROBLASTOMA: A PHASE II STUDY$34,862
M01 · FY2005 · RR
NANT 2001-01:A PHASE I INVESTIGATION OF IL-12/PULSE IL-2 IN CHILDREN$20,550
M01 · FY2005 · RR
IMPACT OF BODY COMPOSITION ON PK OF DOXORUBIN IN PEDIATRIC PATIENTS$17,614
M01 · FY2005 · RR
ANBL02P1: A PILOT INDUCTION REGIMEN INCORPORATING TOPOTECAN FOR NEUROBLASTOMA$11,375
M01 · FY2005 · RR
NANT 2001-03: PHASE I STUDY OF CEP-701 IN PATIENTS WITH REFRACTORY NEUROBLASTOMA$9,174
M01 · FY2005 · RR
NANT #9902: MODULATION OF L-PAM BY BSO WITH AUTOLOGOUS STEM CELL SUPPORT$7,706
M01 · FY2005 · RR
DOSE ESCALATION STUDY OF 131 I-MIBG WITH CHEMOTHERAPY AND STEM CELL RESCUE$6,605
M01 · FY2005 · RR
NANT 2003-01: PHASE I STUDY OF ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME$1,467
M01 · FY2005 · RR
131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*$261,006
R21 · FY2004 · CA
131 I-labeled MIBG for treatment of advanced neuroblastoma: a Phase II study$63,471
M01 · FY2004 · RR
131 I-MIBG double infusion followed by stem cells for refractory neuroblastoma$53,158
M01 · FY2004 · RR
NANT 2001-01:A Phase I investigation of IL-12/Pulse IL-2 in children$36,893
M01 · FY2004 · RR
Impact of body composition on PK of doxorubicin in ped$14,677
M01 · FY2004 · RR
ADVL0116: A phase I trial and PK study of R115777 in pediatric patients$11,505
M01 · FY2004 · RR
NANT 2001-03: Phase I study of CEP-701 in patients with refractory neuroblastoma$7,934
M01 · FY2004 · RR
NANT2002-01: A Phase I study of high dose pyrazoloacridine$3,967
M01 · FY2004 · RR
Phase I intergroup trial of HU14.18-IL.2 fusion protein in children$1,190
M01 · FY2004 · RR
131IMIBG Escalating Dose Rapid Sequence Double Infusion$261,006
R21 · FY2003 · CA
CHILDRENS CANCER GROUP$205,002
U10 · FY2002 · CA
B43-PAP IMMUNOTOXIN WITH 4 DRUG INDUCTION FOR ALL IN RELAPSE$0
M01 · FY2002 · RR
Clinical therapy trials$0
P01 · FY2002 · CA
CCG 09709: FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2002 · RR
CCG 0954: GEMCITABINE IN SOLID TUMORS$0
M01 · FY2002 · RR
CI MERCAPTOPURINE FOLLOWED BY CI ARA-C IN CHILDREN$0
M01 · FY2002 · RR
TRIAL OF TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH PROGRESSIVE CANCER$0
M01 · FY2002 · RR
PHASE I STUDY OF ANTI B4 BLOCKED RICIN IN CHILDREN WITH LEUKEMIA OR LYMPHOMA$0
M01 · FY2002 · RR
PHASE I STUDY OF GAMMA INTERFERON TRANSDUCED NEUROBLASTOMA CELLS$0
M01 · FY2002 · RR
PHASE I STUDY OF D1694 IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2002 · RR
PHASE I STUDY OF CONTINUOUS 21 DAY TOPOTECAN IN CHILDREN WITH RELAPSED TUMORS$0
M01 · FY2002 · RR
PILOT STUDY OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALAN$0
M01 · FY2002 · RR
PHASE I CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY WITH GM-CSF$0
M01 · FY2002 · RR
PHASE I STUDY OF TAXOTERE IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2002 · RR
I-131 MIBG THERAPY FOR NEUROBLASTOMA$0
M01 · FY2002 · RR
PEDIATRIC TRIAL AND PK STUDY OF LGD1057$0
M01 · FY2002 · RR
CHILDRENS CANCER GROUP$196,205
U10 · FY2001 · CA
CI MERCAPTOPURINE FOLLOWED BY CI ARA-C IN CHILDREN$0
M01 · FY2001 · RR
I-131 MIBG THERAPY FOR NEUROBLASTOMA$0
M01 · FY2001 · RR
PHASE I STUDY OF TAXOTERE IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2001 · RR
PHASE I CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY WITH GM-CSF$0
M01 · FY2001 · RR
PILOT STUDY OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALAN$0
M01 · FY2001 · RR
PHASE I STUDY OF CONTINUOUS 21 DAY TOPOTECAN IN CHILDREN WITH RELAPSED TUMORS$0
M01 · FY2001 · RR
PHASE I STUDY OF D1694 IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2001 · RR
PEDIATRIC TRIAL AND PK STUDY OF LGD1057$0
M01 · FY2001 · RR
B43-PAP IMMUNOTOXIN WITH 4 DRUG INDUCTION FOR ALL IN RELAPSE$0
M01 · FY2001 · RR
PHASE I STUDY OF GAMMA INTERFERON TRANSDUCED NEUROBLASTOMA CELLS$0
M01 · FY2001 · RR
PHASE I STUDY OF ANTI B4 BLOCKED RICIN IN CHILDREN WITH LEUKEMIA OR LYMPHOMA$0
M01 · FY2001 · RR
TRIAL OF TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH PROGRESSIVE CANCER$0
M01 · FY2001 · RR
CCG 0954: GEMCITABINE IN SOLID TUMORS$0
M01 · FY2001 · RR
CCG 09709: FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2001 · RR
Clinical therapy trials$0
P01 · FY2001 · CA
I-131 MIBG THERAPY FOR NEUROBLASTOMA$25,799
M01 · FY2000 · RR
PHASE I STUDY OF ANTI B4 BLOCKED RICIN IN CHILDREN WITH LEUKEMIA OR LYMPHOMA$25,799
M01 · FY2000 · RR
PHASE I STUDY OF CONTINUOUS 21 DAY TOPOTECAN IN CHILDREN WITH RELAPSED TUMORS$25,799
M01 · FY2000 · RR
PILOT STUDY OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALAN$25,799
M01 · FY2000 · RR
CI MERCAPTOPURINE FOLLOWED BY CI ARA-C IN CHILDREN$25,799
M01 · FY2000 · RR
PHASE I STUDY OF D1694 IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$25,799
M01 · FY2000 · RR
B43-PAP IMMUNOTOXIN WITH 4 DRUG INDUCTION FOR ALL IN RELAPSE$25,799
M01 · FY2000 · RR
PHASE I STUDY OF GAMMA INTERFERON TRANSDUCED NEUROBLASTOMA CELLS$25,799
M01 · FY2000 · RR
PEDIATRIC TRIAL AND PK STUDY OF LGD1057$25,799
M01 · FY2000 · RR
PHASE I CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY WITH GM-CSF$25,799
M01 · FY2000 · RR
TRIAL OF TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH PROGRESSIVE CANCER$25,799
M01 · FY2000 · RR
PHASE I STUDY OF TAXOTERE IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$25,799
M01 · FY2000 · RR
CCG 09709: FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$17,457
M01 · FY2000 · RR
CCG 0954: GEMCITABINE IN SOLID TUMORS$17,457
M01 · FY2000 · RR
TRIAL OF TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH PROGRESSIVE CANCER$0
M01 · FY2000 · RR
TRIAL OF TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH PROGRESSIVE CANCER$0
M01 · FY2000 · RR
PHASE I STUDY OF ANTI B4 BLOCKED RICIN IN CHILDREN WITH LEUKEMIA OR LYMPHOMA$0
M01 · FY2000 · RR
PHASE I STUDY OF ANTI B4 BLOCKED RICIN IN CHILDREN WITH LEUKEMIA OR LYMPHOMA$0
M01 · FY2000 · RR
PHASE I STUDY OF GAMMA INTERFERON TRANSDUCED NEUROBLASTOMA CELLS$0
M01 · FY2000 · RR
PHASE I STUDY OF GAMMA INTERFERON TRANSDUCED NEUROBLASTOMA CELLS$0
M01 · FY2000 · RR
B43-PAP IMMUNOTOXIN WITH 4 DRUG INDUCTION FOR ALL IN RELAPSE$0
M01 · FY2000 · RR
B43-PAP IMMUNOTOXIN WITH 4 DRUG INDUCTION FOR ALL IN RELAPSE$0
M01 · FY2000 · RR
PEDIATRIC TRIAL AND PK STUDY OF LGD1057$0
M01 · FY2000 · RR
PEDIATRIC TRIAL AND PK STUDY OF LGD1057$0
M01 · FY2000 · RR
PHASE I STUDY OF D1694 IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2000 · RR
PHASE I STUDY OF D1694 IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2000 · RR
PHASE I STUDY OF CONTINUOUS 21 DAY TOPOTECAN IN CHILDREN WITH RELAPSED TUMORS$0
M01 · FY2000 · RR
PHASE I STUDY OF CONTINUOUS 21 DAY TOPOTECAN IN CHILDREN WITH RELAPSED TUMORS$0
M01 · FY2000 · RR
PILOT STUDY OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALAN$0
M01 · FY2000 · RR
PILOT STUDY OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALAN$0
M01 · FY2000 · RR
PHASE I CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY WITH GM-CSF$0
M01 · FY2000 · RR
PHASE I CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY WITH GM-CSF$0
M01 · FY2000 · RR
PHASE I STUDY OF TAXOTERE IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2000 · RR
PHASE I STUDY OF TAXOTERE IN PEDIATRIC PATIENTS WITH ADVANCED NEOPLASTIC DISEASE$0
M01 · FY2000 · RR
I-131 MIBG THERAPY FOR NEUROBLASTOMA$0
M01 · FY2000 · RR
I-131 MIBG THERAPY FOR NEUROBLASTOMA$0
M01 · FY2000 · RR
Clinical therapy trials$0
P01 · FY2000 · CA
PACLITAXEL IN REFRACTORY LEUKEMIA IN CHILDREN$0
M01 · FY2000 · RR
PACLITAXEL IN REFRACTORY LEUKEMIA IN CHILDREN$0
M01 · FY2000 · RR
PACLITAXEL IN REFRACTORY LEUKEMIA IN CHILDREN$0
M01 · FY2000 · RR
THROMBOPOIETIN &G-CSF IN CHILD SOLID TUMORS$0
M01 · FY2000 · RR
THROMBOPOIETIN &G-CSF IN CHILD SOLID TUMORS$0
M01 · FY2000 · RR
THROMBOPOIETIN &G-CSF IN CHILD SOLID TUMORS$0
M01 · FY2000 · RR
CCG 09709: FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2000 · RR
CCG 09709: FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2000 · RR
CCG 0954: GEMCITABINE IN SOLID TUMORS$0
M01 · FY2000 · RR
CCG 0954: GEMCITABINE IN SOLID TUMORS$0
M01 · FY2000 · RR
CI MERCAPTOPURINE FOLLOWED BY CI ARA-C IN CHILDREN$0
M01 · FY2000 · RR
CI MERCAPTOPURINE FOLLOWED BY CI ARA-C IN CHILDREN$0
M01 · FY2000 · RR